Metformin Reduces Oxidative Damage in RNASEH2-Mutant Aicardi-Goutières Cells
Genes · 2025
DOI: 10.3390/genes16080922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Francesca Dragoni und 10 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Mondino Foundation, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Metformin, Oxidative Stress, Autoimmune Diseases of the Nervous System, Nervous System Malformations. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Ministero della Salute, NIH HHS.
Abstract (Originalsprache)
Background
Aicardi-Goutières Syndrome (AGS) is a rare neuroinflammatory condition characterized by early-onset symptoms that extend outside the nervous system. Due to the rarity of the disease, the pathogenesis is not well understood, and its diagnosis and treatment remain elusive. We recently demonstrated mitochondrial abnormalities and increased reactive oxygen species (ROS) levels in lymphoblastoid cell lines (LCLs) derived from RNASEH2B- and RNASEH2A-mutated AGS patients. On this background, we turned our attention to metformin, the first-choice drug for type 2 diabetes, as a possible treatment acting on oxidative stress in RNASEH2-mutant AGS cells. Methods and Results: By means of flow cytometry, we found that metformin treatment significantly decreases ROS production in RNASEH2B- and RNASEH2A-mutated AGS LCLs. Of note, metformin treatment reduces the green JC-1 monomeric signal and, concurrently, increases the red JC-1 signal in both mutated LCLs, accounting for restoration of the mitochondrial membrane potential. Immunofluorescence staining shows a decrease in 8-oxoG levels only in RNASEH2B- mutated AGS LCLs. Finally, the significant upregulation of Forkhead Box O3 (FOXO3), cytochrome C somatic (CYCS), and superoxide dismutase 2 (SOD2) mRNA levels in RNASEH2B-mutated AGS LCLs after metformin treatment points to FOXO3 signaling as a possible mechanism to reduce oxidative stress.
Conclusions
In conclusion, even if these pilot results need to be confirmed on a larger cohort, we shed light on metformin treatment as a valid approach to ameliorate oxidative stress-related inflammation in AGS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Mondino Foundation, 27100 Pavia, Italy.
- Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
- Department of Pediatric, Buzzi Children's Hospital, 20154 Milan, Italy.
- Department of Biomedical and Clinical Sciences, University of Milan, 20122 Milan, Italy.
ORCID-Profile: Francesca Dragoni, Jessica Garau, Bartolo Rizzo, Simona Orcesi, Costanza Varesio, Rosalinda Di Gerlando, Matteo Bordoni, Eveljn Scarian, Cristina Cereda, Orietta Pansarasa, Stella Gagliardi
Förderung
- NINDS NIH HHS
- Ministero della Salute
- NIH HHS
- NIH
- Ricerca Corrente 2025–2027, Italian Ministry of Health
Zitieren
APA
Dragoni, F., Garau, J., Rizzo, B., Orcesi, S., Varesio, C., Di Gerlando, R., Bordoni, M., Scarian, E., Cereda, C., Pansarasa, O., & Gagliardi, S. (2025). Metformin Reduces Oxidative Damage in RNASEH2-Mutant Aicardi-Goutières Cells. Genes. https://doi.org/10.3390/genes16080922
Vancouver
Dragoni F, Garau J, Rizzo B, Orcesi S, Varesio C, Di Gerlando R, et al. Metformin Reduces Oxidative Damage in RNASEH2-Mutant Aicardi-Goutières Cells. Genes. 2025. doi:10.3390/genes16080922
BibTeX
@article{Dragoni2025,
author = {Dragoni, Francesca and Garau, Jessica and Rizzo, Bartolo and Orcesi, Simona and Varesio, Costanza and Di Gerlando, Rosalinda and Bordoni, Matteo and Scarian, Eveljn and Cereda, Cristina and Pansarasa, Orietta and Gagliardi, Stella},
title = {Metformin Reduces Oxidative Damage in RNASEH2-Mutant Aicardi-Goutières Cells},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16080922}
}
EUVIMED